Meeting
2015 ASCO Annual Meeting
Changes in blood eosinophilia during anti-PD1 therapy as a predictor of long term disease control in metastatic melanoma.
Authors
Lydia Gaba
Hospital Clinic de Barcelona, Barcelona, Spain
Lydia Gaba , Iván Victoria , Estela Pineda , Aranzazu Fernandez , Francisco Aya , Aleix Prat , Ana M Arance
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Citation
J Clin Oncol 33, 2015 (suppl; abstr 9069)
DOI
10.1200/jco.2015.33.15_suppl.9069
Abstract #
9069
Poster Bd #
312
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
First Author: Caroline Robert
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane
Poster
2020 ASCO Virtual Scientific Program
The impact of BRAF mutation status on clinical outcomes with single-agent PD-1 inhibitor versus combination ipilimumab/nivolumab.
First Author: Vincent The-Luc Ma
Poster
2017 ASCO-SITC Clinical Immuno-Oncology Symposium
Blood eosinophil counts as predictive marker in advanced melanoma patients treated with anti-PD1 therapies.
First Author: Lydia Gaba